Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial. 1982

D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001388 Aziridines Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms. Ethyleneimines,Azacyclopropanes, Saturated,Dimethyleneimines,Saturated Azacyclopropanes
D001389 Azirines Unsaturated azacyclopropane compounds that are three-membered heterocycles of a nitrogen and two carbon atoms. Azacyclopropanes, Unsaturated,Unsaturated Azacyclopropanes

Related Publications

D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
January 1983, Cancer treatment reports,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
December 1982, Cancer treatment reports,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
October 1982, American journal of clinical oncology,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
May 1983, Cancer treatment reports,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
June 1999, American journal of clinical oncology,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
October 1986, Cancer treatment reports,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
January 1985, Cancer treatment reports,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
December 1982, Cancer treatment reports,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
January 1988, Cancer investigation,
D R Budman, and A Forastiere, and M Perloff, and M Perry, and J Aisner, and V Weinberg, and W Wood
November 1982, Cancer treatment reports,
Copied contents to your clipboard!